Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline

Kymera Therapeutics (KYMR) announced significant pipeline and partnership updates, including an $85 million upfront payment from Gilead Sciences for a new oncology collaboration targeting CDK2 degraders, with potential for up to $750 million plus royalties. Concurrently, Sanofi opted to discontinue the Phase IIb KT-474, instead advancing the preclinical IRAK4 degrader KT-485, triggering a $20 million milestone payment and potential for $975 million, though this decision shifts the timeline for prior milestone expectations. Internally, Kymera's KT-621 demonstrated strong Phase I results in atopic dermatitis, comparable to Dupixent, with Phase 2b trials anticipated in late 2025/early 2026, highlighting continued progress in its targeted protein degradation platform.

Analysis

Kymera Therapeutics (KYMR) has announced a significant strategic realignment of its pipeline and partnerships, marked by both a major new collaboration and a pivot within an existing one. The new exclusive option agreement with Gilead Sciences for a CDK2-targeting molecular glue degrader program provides substantial validation and non-dilutive funding, including an $85 million upfront payment and a total potential value of up to $750 million plus royalties. This deal validates Kymera's platform in the oncology space. Concurrently, the Sanofi partnership has been revised; while Sanofi discontinued the Phase IIb development of KT-474, it has advanced a different Kymera-discovered candidate, KT-485, into clinical development. This shift triggered a $20 million milestone payment and maintains a potential deal value of up to $975 million, but it materially resets the development timeline for the IRAK4 degrader program, pushing potential major revenue events further out. Separately, Kymera's proprietary pipeline shows strong momentum, with its STAT6 degrader, KT-621, demonstrating efficacy comparable to the blockbuster drug Dupixent in a Phase I study, with Phase IIb trials planned for late 2025 to early 2026.

Key Decisions for Investors

• Investors should view the Gilead partnership as a significant de-risking event, providing an immediate $85 million cash infusion and external validation of Kymera's molecular glue degrader platform in oncology.
• It is critical to recalibrate models to account for the delayed revenue timeline from the Sanofi collaboration, as the discontinuation of the Phase IIb asset KT-474 pushes significant milestone payments further into the future, despite the continued partnership with the earlier-stage KT-485.
• Upcoming catalysts to monitor closely are the Phase 1b data for KT-621 expected in Q4 2025 and the subsequent initiation of Phase IIb studies, as positive outcomes would reinforce the candidate's blockbuster potential in atopic dermatitis and asthma.